Ophthotech Corporation - Company & Market Research Reports

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.


Ocular Cancer Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Ocular Cancer Drug Development Pipeline Review, 2018

  • Report
  • 63 Pages
From
Ocular Drug Delivery: Market Overview, Delivery Technologies, and Partnering Opportunities - Product Thumbnail Image

Ocular Drug Delivery: Market Overview, Delivery Technologies, and Partnering Opportunities

  • Report
  • 144 Pages
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update - Product Thumbnail Image

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update

  • Report
  • 462 Pages
From
Age-Related Macular Degeneration Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments - Product Thumbnail Image

Age-Related Macular Degeneration Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • Report
  • 143 Pages
From
Ophthalmology Drug Development Pipeline Review, 2016 - Product Thumbnail Image

Ophthalmology Drug Development Pipeline Review, 2016

  • Report
  • 633 Pages
From
Uveitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Uveitis - Pipeline Review, H1 2018

  • Report
  • 195 Pages
From
Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors - Product Thumbnail Image

Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors

  • Report
  • 1342 Pages
From
Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030 - Product Thumbnail Image

Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030

  • Report
  • 292 Pages
From
Global Ophthalmology Drugs Market Analysis 2016 - Forecast to 2022 - Product Thumbnail Image

Global Ophthalmology Drugs Market Analysis 2016 - Forecast to 2022

  • Report
  • 127 Pages
From
Global Age-Related Macular Degeneration (AMD) Market Size, Share, Development, Growth and Demand Forecast to 2022 - Industry Insights by Type (Dry AMD, and Wet AMD), by Drug (Lucentis, Eylea, Visudyne, Avastin and Others) - Product Thumbnail Image

Global Age-Related Macular Degeneration (AMD) Market Size, Share, Development, Growth and Demand Forecast to 2022 - Industry Insights by Type (Dry AMD, and Wet AMD), by Drug (Lucentis, Eylea, Visudyne, Avastin and Others)

  • Report
From
Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview  - Product Thumbnail Image

Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview

  • Report
  • 208 Pages
From
Age Related Macular Degeneration - Pipeline Review, H2 2017 - Product Thumbnail Image

Age Related Macular Degeneration - Pipeline Review, H2 2017

  • Report
  • 537 Pages
From
Retinal Degeneration - Pipeline Insight, 2018 - Product Thumbnail Image

Retinal Degeneration - Pipeline Insight, 2018

  • Drug Pipelines
  • 217 Pages
From
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2018 - Product Thumbnail Image

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2018

  • Report
  • 79 Pages
From
Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026 - Product Thumbnail Image

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026

  • Report
  • 319 Pages
From
Age Related Macular Degeneration - Pipeline Review, H1 2017 - Product Thumbnail Image

Age Related Macular Degeneration - Pipeline Review, H1 2017

  • Report
  • 527 Pages
From
OpportunityAnalyzer:Uveitis - Opportunity Analysis and Forecasts to 2026 - Product Thumbnail Image

OpportunityAnalyzer:Uveitis - Opportunity Analysis and Forecasts to 2026

  • Drug Pipelines
  • 244 Pages
From
Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016 - Product Thumbnail Image

Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016

  • Report
  • 136 Pages
From
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016 - Product Thumbnail Image

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

  • Report
  • 267 Pages
From
Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016 - Product Thumbnail Image

Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016

  • Report
  • 141 Pages
From
Loading Indicator
adroll